255 related articles for article (PubMed ID: 26256928)
1. [Acquired von Willebrand syndrome in a patient with immune thrombocytopenic purpura].
Ihara A; Suzuki N; Matsushita T; Ichinose A
Rinsho Ketsueki; 2015 Jul; 56(7):901-4. PubMed ID: 26256928
[TBL] [Abstract][Full Text] [Related]
2. Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome.
Hong S; Lee J; Chi H; Lee C; Nah S; Kim Y; Oh J; Moon H; Yoo B
Lupus; 2008 Sep; 17(9):846-8. PubMed ID: 18755868
[TBL] [Abstract][Full Text] [Related]
3. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
4. A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome.
Franchi F; Biguzzi E; Stufano F; Siboni SM; Baronciani L; Peyvandi F
Thromb Res; 2014 Dec; 134(6):1316-22. PubMed ID: 25300810
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
7. Association of acquired von Willebrand syndrome with AL amyloidosis.
Kos CA; Ward JE; Malek K; Sanchorawala V; Wright DG; O'Hara C; Connors L; Skinner M; Seldin DC
Am J Hematol; 2007 May; 82(5):363-7. PubMed ID: 17205535
[TBL] [Abstract][Full Text] [Related]
8. [Acquired immune-mediated von Willebrand syndrome accompanied by antiphospholipid syndrome].
Kobayashi N; Ogawa Y; Yanagisawa K; Ishizaki T; Uchiumi H; Suzuki N; Matsushita T; Ichinose A; Handa H
Rinsho Ketsueki; 2017; 58(6):613-618. PubMed ID: 28679991
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand's syndrome: a single institution experience.
Kumar S; Pruthi RK; Nichols WL
Am J Hematol; 2003 Apr; 72(4):243-7. PubMed ID: 12666134
[TBL] [Abstract][Full Text] [Related]
10. Rituximab effectiveness in a patient with juvenile systemic lupus erythematosus complicated with acquired Von Willebrand syndrome.
Jimenez AR; Vallejo ES; Cruz MZ; Cruz AC; Miramontes JV; Jara BS
Lupus; 2013 Dec; 22(14):1514-7. PubMed ID: 23989733
[TBL] [Abstract][Full Text] [Related]
11. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.
Stuijver DJ; Piantanida E; van Zaane B; Galli L; Romualdi E; Tanda ML; Meijers JC; Büller HR; Gerdes VE; Squizzato A
Haemophilia; 2014 May; 20(3):326-32. PubMed ID: 24118466
[TBL] [Abstract][Full Text] [Related]
12. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.
Casonato A; Pontara E; Doria A; Bertomoro A; Cattini MG; Gambari PF; Girolami A
Br J Haematol; 2002 Mar; 116(4):899-904. PubMed ID: 11886398
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
14. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
Federici AB
Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of acquired von Willebrand syndrome.
Tiede A
Thromb Res; 2012 Dec; 130 Suppl 2():S2-6. PubMed ID: 23439003
[TBL] [Abstract][Full Text] [Related]
16. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
17. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
18. A case of autoimmune severe acquired von Willebrand syndrome (type 3-like).
Gavva C; Patel P; Shen YM; Frenkel E; Sarode R
Transfus Apher Sci; 2017 Jun; 56(3):431-433. PubMed ID: 28512017
[TBL] [Abstract][Full Text] [Related]
19. Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus.
Niiya M; Niiya K; Takazawa Y; Hayashi Y; Tanio Y; Kushiro M; Tanimizu M; Hasegawa H; Tanimoto M
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):361-5. PubMed ID: 12032403
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]